{"id":2766,"date":"2026-02-27T22:13:46","date_gmt":"2026-02-28T03:13:46","guid":{"rendered":"https:\/\/lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/"},"modified":"2026-02-27T22:51:45","modified_gmt":"2026-02-28T03:51:45","password":"","slug":"screening-of-neoantigen-hla-complexes","status":"publish","type":"docs","link":"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/","title":{"rendered":"Screening of Neoantigen HLA Complexes"},"content":{"rendered":"

Mutated peptides, known as neoantigens, derived from a patient’s cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding but struggle to account for the half-lives of these complexes (a critical immunological parameter called kinetic stability). Enhancing our ability to determine the true stability of neoantigen peptide\/MHC complexes is crucial, as only a small fraction of peptides in current vaccines effectively trigger CD8+ T-cell responses.<\/p>\n

A study utilized a rapid, high-throughput approach to experimentally measure peptide\/HLA thermal stability on a scale needed for analyzing neoantigens from thousands of patients. By combining UV-cleavable peptide\/HLA class I complexes with differential scanning fluorimetry, the Tm values of neoantigen complexes were determined. These Tm values were accurate, reproducible, and directly proportional to the complexes’ half-lives. When analyzing known HLA-A2\u2013restricted immunogenic peptides, Tm values correlated more strongly with immunogenicity than algorithm-predicted binding affinities. Using temperature stability information can help select neoantigens for cancer vaccines, focusing on mutated peptides most likely to be expressed on the cell surface.<\/p>\n

Tm analysis of HLA-A2 complexes containing immunogenic neoantigen peptides<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Gene<\/th>\nSequence<\/th>\n <\/th>\nTm (\u00b0C)<\/th>\n<\/tr>\n<\/thead>\n
\u2003ME-1<\/em> <\/td>\nFLDEFMEGV <\/td>\n <\/td>\n63.2 \u00b1 0.4 <\/td>\n<\/tr>\n
\u2003FNDC3B<\/em> <\/td>\nVVMSWAPPV <\/td>\n <\/td>\n61.6 \u00b1 0.6 <\/td>\n<\/tr>\n
\u2003PRDX5<\/em> <\/td>\nLLLDDLLVSI <\/td>\n <\/td>\n55.3 \u00b1 0.7 <\/td>\n<\/tr>\n
\u2003GAS7<\/em> <\/td>\nSLADEAEVYL <\/td>\n <\/td>\n59.2 \u00b1 0.7 <\/td>\n<\/tr>\n
\u2003KIAA0223<\/em> <\/td>\nVLHDDLLEA <\/td>\n <\/td>\n59.7 \u00b1 0.5 <\/td>\n<\/tr>\n
\u2003GAPDH<\/em> <\/td>\nGIVEGLITTV <\/td>\n <\/td>\n58.5 \u00b1 0.6 <\/td>\n<\/tr>\n
\u2003HSP70<\/em> <\/td>\nSLFEGIDIYT <\/td>\n <\/td>\n59.8 \u00b1 0.6 <\/td>\n<\/tr>\n
\u2003ACTININ<\/em> <\/td>\nFIASNGVKLV <\/td>\n <\/td>\n56.9 \u00b1 0.5 <\/td>\n<\/tr>\n
\u2003HAUS3<\/em> <\/td>\nILNAMIAKI <\/td>\n <\/td>\n56.9 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003CSNK1A1<\/em> <\/td>\nGLFGDIYLAI <\/td>\n <\/td>\n52.6 \u00b1 0.6 <\/td>\n<\/tr>\n
\u2003CLPP<\/em> <\/td>\nILDKVLVHL <\/td>\n <\/td>\n57.1 \u00b1 0.4 <\/td>\n<\/tr>\n
\u2003CDK4<\/em> <\/td>\nACDPHSGHFV <\/td>\n <\/td>\n59.9 \u00b1 0.3 <\/td>\n<\/tr>\n
\u2003AHNAK<\/em> <\/td>\nFMPDFDLHL <\/td>\n <\/td>\n60.1 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003SRPX<\/em> <\/td>\nTLWCSPIKV <\/td>\n <\/td>\n63.7 \u00b1 0.1 <\/td>\n<\/tr>\n
\u2003COL18A1<\/em> <\/td>\nVLLGVKLFGV <\/td>\n <\/td>\n60.9 \u00b1 0.3 <\/td>\n<\/tr>\n
\u2003ERBB2<\/em> <\/td>\nALIHHNTYL <\/td>\n <\/td>\n59.4 \u00b1 0.5 <\/td>\n<\/tr>\n
\u2003TEAD1<\/em> <\/td>\nVLENFTIFLV <\/td>\n <\/td>\n48.2 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003TEAD1<\/em> <\/td>\nSVLENFTIFL <\/td>\n <\/td>\n55.8 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003NSDHL<\/em> <\/td>\nILTGLNYEV <\/td>\n <\/td>\n61.4 \u00b1 0.1 <\/td>\n<\/tr>\n
\u2003GANAB<\/em> <\/td>\nALYGFVPVL <\/td>\n <\/td>\n61.7 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003CDC37L1<\/em> <\/td>\nFLSDHLYLV <\/td>\n <\/td>\n61.8 \u00b1 0.1 <\/td>\n<\/tr>\n
\u2003FLNA<\/em> <\/td>\nHIAKSLFEV <\/td>\n <\/td>\n56.4 \u00b1 0.4 <\/td>\n<\/tr>\n
\u2003SPOP<\/em> <\/td>\nFLLDEAIGL <\/td>\n <\/td>\n60.7 \u00b1 0.1 <\/td>\n<\/tr>\n
\u2003ACPP<\/em> <\/td>\nVLAKKLKFV <\/td>\n <\/td>\n56.8 \u00b1 0.7 <\/td>\n<\/tr>\n
\u2003DCAKD<\/em> <\/td>\nLLHTELERFL <\/td>\n <\/td>\n42.9 \u00b1 0.2 <\/td>\n<\/tr>\n
\u2003CIT<\/em> <\/td>\nTLLSQVNKV <\/td>\n <\/td>\n53.2 \u00b1 0.3 <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Mutated peptides, known as neoantigens, derived from a patient’s cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"doc_category":[331],"doc_tag":[],"class_list":["post-2766","docs","type-docs","status-publish","hentry","doc_category-technical-protocols"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\n","aioseo_head_json":{"title":"Screening of Neoantigen HLA Complexes | LifeTein Peptide Blog","description":"Mutated peptides, known as neoantigens, derived from a patient's cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding but struggle to account for the half-lives of these complexes (a critical immunological parameter called","canonical_url":"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"xKDW6DUiGuZ6nwglNeWlVWTgzTtMPzas13ROL63ytTc","msvalidate.01":"5B15601215D876311F84CFEFB0F72F18","miscellaneous":""},"schema":null,"og:locale":"en_US","og:site_name":"LifeTein Peptide Synthesis Blog","og:type":"article","og:title":"Screening of Neoantigen HLA Complexes | LifeTein Peptide Blog","og:description":"Mutated peptides, known as neoantigens, derived from a patient's cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding but struggle to account for the half-lives of these complexes (a critical immunological parameter called","og:url":"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/","fb:admins":"233983946638783","og:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","og:image:secure_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","article:published_time":"2026-02-28T03:13:46+00:00","article:modified_time":"2026-02-28T03:51:45+00:00","article:publisher":"https:\/\/www.facebook.com\/LifeTein-LLC-233983946638783\/","twitter:card":"summary_large_image","twitter:site":"@lifetein","twitter:title":"Screening of Neoantigen HLA Complexes | LifeTein Peptide Blog","twitter:description":"Mutated peptides, known as neoantigens, derived from a patient's cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding but struggle to account for the half-lives of these complexes (a critical immunological parameter called","twitter:creator":"@lifetein","twitter:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg"},"aioseo_meta_data":{"post_id":"2766","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"location":null,"local_seo":null,"seo_analyzer_scan_date":null,"breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":null,"created":"2026-02-28 03:13:46","updated":"2026-02-28 03:56:49"},"aioseo_breadcrumb":"

\n\t\t\tHome<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tDocs<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tTechnical Protocols<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tScreening of Neoantigen HLA Complexes\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.lifetein.com\/blog"},{"label":"Docs","link":"https:\/\/www.lifetein.com\/blog\/docs\/"},{"label":"Technical Protocols","link":"https:\/\/www.lifetein.com\/blog\/docs-category\/technical-protocols\/"},{"label":"Screening of Neoantigen HLA Complexes","link":"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/"}],"year_month":"2026-07","word_count":363,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"lifetein","author_nicename":"new_blog","author_url":"https:\/\/www.lifetein.com\/blog\/author\/new_blog\/"},"doc_category_info":[{"term_name":"Technical Protocols","term_url":"https:\/\/www.lifetein.com\/blog\/docs-category\/technical-protocols\/"}],"doc_tag_info":[],"_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/docs"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=2766"}],"version-history":[{"count":1,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766\/revisions"}],"predecessor-version":[{"id":2803,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766\/revisions\/2803"}],"wp:attachment":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media?parent=2766"}],"wp:term":[{"taxonomy":"doc_category","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_category?post=2766"},{"taxonomy":"doc_tag","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_tag?post=2766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}